Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

Reviewer-ready, comprehensive on- and off-target analysis for your CRISPR project, from research to clinical applications

Get a free consultation from one of our CRISPR experts for off-target nomination or on/off target confirmation.


Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
IDT is a global leader in CRISPR genome editing solutions supporting researchers and cell and gene therapy developers. Ensuring the safety and efficacy of your cell and gene therapy program earlier in the discovery process is more critical than ever. Outsource your CRISPR on-and off-target analysis to enable reliable gene editing safety assessments for IND enabling studies and novel publications based on the latest guidance from regulatory bodies.

Why choose our comprehensive CRISPR analysis services for nomination and confirmation?
  1. The gold standard in comprehensive end-to-end assessments: Utilize the highest sensitivity next-generation sequencing-based off-target analysis technology, UNCOVERseq™, alongside the award-winning rhAmpSeq™ CRISPR Analysis System for on- and off-target confirmation for your pre- clinical therapeutic development.
  2. Robust performance, rigorous analytical and process standards: Experience highly reproducible assays with analytical sensitivities driven by empirical data for both nomination and confirmation assays.
  3. Expert regulatory support: Navigate complex FDA and EMA guidance for IND-enabling projects with our specialized regulatory support, tailored to meet the stringent requirements of your therapeutic development.
  4. Comprehensive reviewer-ready reporting: Receive in-depth reports for on off-target nomination and confirmation, featuring site prioritization and recommended confirmation panels, providing you with actionable insights for your research or therapy development.
  5. Dedicated CRISPR team: Partner with our team of CRISPR experts, committed to your project's success from inception to completion, ensuring personalized support and expert guidance throughout the entire process.
Let's take your CRISPR therapeutics research into the clinic! Rapidly move from the lab to publishing and therapeutic clinical trials. We'll help.

Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
24-GE-LP-SeQure-Dx-Partnership-sandy-ottensmann.png

“At IDT, we are committed to advancing the field of CRISPR therapeutics by providing our customers with the most comprehensive and reliable solutions. Our partnership with SeQure Dx enables us to deliver off-target editing analytical services that streamline the entire development process, from research to clinical applications.”  

—Sandy Ottensmann, IDT Vice President and General Manager of Gene Writing and Editing

24-GE-LP-SeQure-Dx-Partnership-Keith-Young.png

“SeQure's best-in-class off-target nomination and confirmation platforms will seamlessly complement IDT’s CRISPR-based portfolio of products and services. Combining SeQure’s and IDT’s innovative technologies will enhance precision and safety in gene editing, bringing transformative solutions to researchers and patients worldwide.”

—Keith Joung, SeQure Dx Scientific Founder